La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Argent BioPharma Gestion

Gestion contrôle des critères 4/4

Argent BioPharma's CEO is Roby Zomer, appointed in Feb 2016, has a tenure of 8.5 years. total yearly compensation is A$354.02K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.07% of the company’s shares, worth A$8.46K. The average tenure of the management team and the board of directors is 2.1 years and 3.6 years respectively.

Informations clés

Roby Zomer

Directeur général

AU$354.0k

Rémunération totale

Pourcentage du salaire du PDG	100.0%
Durée du mandat du directeur général	8.5yrs
Propriété du PDG	0.07%
Durée moyenne d'occupation des postes de direction	2.1yrs
Durée moyenne du mandat des membres du conseil d'administration	3.6yrs

Mises à jour récentes de la gestion

Recent updates

If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% Returns

Feb 21

What Does MGC Pharmaceuticals' (ASX:MXC) CEO Pay Reveal?

Dec 30

Analyse de la rémunération des PDG

Comment la rémunération de Roby Zomer a-t-elle évolué par rapport aux bénéfices de Argent BioPharma?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Dec 31 2023	n/a	n/a	-AU$17m
Sep 30 2023	n/a	n/a	-AU$19m
Jun 30 2023	AU$354k	AU$354k	-AU$21m
Mar 31 2023	n/a	n/a	-AU$22m
Dec 31 2022	n/a	n/a	-AU$23m
Sep 30 2022	n/a	n/a	-AU$22m
Jun 30 2022	AU$629k	AU$422k	-AU$20m
Mar 31 2022	n/a	n/a	-AU$19m
Dec 31 2021	n/a	n/a	-AU$18m
Sep 30 2021	n/a	n/a	-AU$17m
Jun 30 2021	AU$481k	AU$281k	-AU$16m
Dec 31 2020	n/a	n/a	-AU$13m
Sep 30 2020	n/a	n/a	-AU$16m
Jun 30 2020	AU$440k	AU$290k	-AU$19m
Dec 31 2019	n/a	n/a	-AU$18m
Sep 30 2019	n/a	n/a	-AU$14m
Jun 30 2019	AU$495k	AU$330k	-AU$11m
Dec 31 2018	n/a	n/a	-AU$7m
Sep 30 2018	n/a	n/a	-AU$7m
Jun 30 2018	AU$498k	AU$334k	-AU$8m

Rémunération vs marché: Roby's total compensation ($USD237.82K) is about average for companies of similar size in the Australian market ($USD299.11K).

Rémunération et revenus: Roby's compensation has been consistent with company performance over the past year.

PDG

Roby Zomer (44 yo)

8.5yrs

Titularisation

AU$354,018

Compensation

Mr. Roby Reuven Zomer is a Co-Founder of Argent BioPharma Limited (formerly known as MGC Pharmaceuticals Limited) and served as its Interim Chief Financial Officer since April 2022 until April 2022. Mr. Zo...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Roby Zomer	Co-Founder	8.5yrs	AU$354.02k	0.070% A$ 8.5k
Igor Bluvstein	Chief Financial Officer	less than a year	pas de données	pas de données
Yifat Steuer	Deputy CEO & COO	1.8yrs	pas de données	37.79% A$ 4.6m
Tom Cairns	Chief Accounting Officer	1.5yrs	pas de données	pas de données
Nicole Godresse	Global Chief Sales Officer	3.6yrs	pas de données	pas de données
Amir Polak	Chief Pharmaceutical Development Officer	no data	pas de données	pas de données
Sabina Suljakovic	Head of the Quality Assurance Department	3.9yrs	pas de données	pas de données
Nadya Lisovoder	Chief Medical Officer	no data	pas de données	pas de données
Sasha Friedman	Deputy CEO	no data	pas de données	pas de données
Yair Tal	Chief Information Security Officer	no data	pas de données	pas de données
Robert Clements	Chief Commercial Officer	2.1yrs	pas de données	pas de données
Itay Nissim	Chief Manufacturing & Supply Chain Officer	no data	pas de données	pas de données

2.1yrs

Durée moyenne de l'emploi

Gestion expérimentée: RGT's management team is considered experienced (2.1 years average tenure).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Roby Zomer	Co-Founder	8.5yrs	AU$354.02k	0.070% A$ 8.5k
Ross Grant Walker	Chairman of Strategic Advisory Board	no data	AU$44.00k	0.010% A$ 1.2k
Uri Kramer	Member of Strategic Advisory Board	8.1yrs	pas de données	pas de données
Layton Mills	Independent Non-Executive Director	1.2yrs	pas de données	pas de données
Wendyl D'Souza	Member of Medical Advisory Board	6.1yrs	pas de données	pas de données
Daniel Robinson	Non-Executive Director	less than a year	pas de données	pas de données
Shlomo Sadoun	Member of Advisory Board	less than a year	pas de données	pas de données

3.6yrs

Durée moyenne de l'emploi

Conseil d'administration expérimenté: RGT's board of directors are considered experienced (3.6 years average tenure).

Argent BioPharma Gestion

Gestion contrôle des critères 4/4

Informations clés

Mises à jour récentes de la gestion

Argent Biopharma Limited Announces the Appointment of Mr. Igor Bluvstein as Chief Financial Officer

Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board

Less than half of directors are independent

MGC Pharmaceuticals Limited Announces Board Changes

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2023

MGC Pharmaceuticals Limited Announces Executive Changes

Recent updates

New minor risk - Share price stability

Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New major risk - Market cap size

Argent Biopharma Limited Announces the Appointment of Mr. Igor Bluvstein as Chief Financial Officer

Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board

New major risk - Market cap size

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.74 million.

MGC Pharmaceuticals Limited's Product Artemic Receives FDA Approval in Saudi Arabia

Less than half of directors are independent

MGC Pharmaceuticals Limited Announces Board Changes

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 12.4 million.

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New major risk - Shareholder dilution

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New minor risk - Financial data availability

MGC Pharmaceuticals Limited Announces Positive Pre-Clinical Trial Results on CimetrA®

MGC Pharmaceuticals Limited Announces Executive Changes

MGC Pharmaceuticals Limited Announces Resignation of Arron Canicais, Joint Company Secretary

New major risk - Shareholder dilution

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of £0.65 million.

New major risk - Market cap size

MGC Pharmaceuticals Limited Announces Appointment of Layton Mills as Non-Executive Director

MGC Pharmaceuticals Limited Announces Board Changes, Effective 1 June 2023

First half 2023 earnings released: AU$0.004 loss per share (vs AU$0.003 loss in 1H 2022)

MGC Pharmaceuticals Limited Announces Change of CFO

MGC Pharmaceuticals Ltd Completes the Pre-Clinical Rodent Studies on Cimetratm

Less than half of directors are independent

MGC Pharmaceuticals Limited Announces Resignation of Evan Hayes as Director

MGC Pharmaceuticals Limited Announces Completion of CimetrA Efficacy Pre-Clinical Trial

Price target decreased to AU$0.04

Mgc Pharmaceuticals Ltd Announces the Results of the Open Label Clinical Study, a White Label Version of ArtemiCTM Support

MGC Pharmaceuticals Limited Provides an Update on Its Operations

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 24, 2022

Mgc Pharmaceuticals Limited Announces Board Changes

Full year 2022 earnings: EPS and revenues miss analyst expectations

MGC Pharmaceuticals Successfully Developed Herbal-Inspired Products for Treatment of Long Covid and Covid-19

MGC Pharmaceuticals Limited Announces Interim Results from the Data Collected from the Initial 16 Patients Participating in the CimetrA Dose Finding Study

MGC Pharmaceuticals Limited, Annual General Meeting, Oct 05, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

MGC Pharmaceuticals Ltd Provides the Following Results from A Recently Completed Randomised, Double Blind, Placebo Controlled Study Investigating the Effect of MGC's Pharma's Epilepsy Treatment, Cannepil®, on Vehicle Driving Performance, Sedation and Mood (Trial)

Price target decreased to AU$0.07

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10 million in funding from Mercer Street Capital Partners, LLC

Mgc Pharmaceuticals Ltd Announces Appointment of Mr. Robert Clements as Chief Commercial Officer

MGC Pharmaceuticals Limited Announces Long COVID Study Results for Artemic Support

MGC Pharmaceuticals Limited Receives Approval Granted for the Dose Finding Study of CimetrA on Patients Diagnosed With Covid-19

MGC Pharmaceuticals Limited Announces the Launch of ZAM- Medical Data App in Collaboration with Caba Tech

MGC Pharmaceuticals Limited Announces CimetrA Pre-Clinical Trial Progress Report

Mgc Pharmaceuticals Limited Announces Cimetra Clinical Trial Progress

MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

MGC Pharmaceuticals Ltd Has Completes Successful In-Vitro Preclinical Research Study into the Use of Cannabinoids to Treat Glioblastoma Multiforme Cells, A Fast-Growing and Aggressive Form of Brain Cancer

Mgc Pharmaceuticals Ltd to Provide Details of the Results of Its Phase II Clinical Trial into the Effect of Its Proprietary Investigational Medicinal Product, CogniCann

MGC Pharmaceuticals Ltd Patent Application forCannEpil®Drug Delivery System Patent granted by European IP Office

Mgc Pharmaceuticals Limited Announces Appointment of Angela-Marie Graham as Its New London Based Chief Financial Officer

MGC Pharmaceuticals Ltd Announces Patent Application for CimetrATM Approve by European IP Office

MGC Pharmaceuticals Limited Announces Executive Changes

MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

MGC Pharmaceuticals Ltd Receives an Import Approval Permit for the Importation of ArtemiCTM Rescue into India

Swiss PharmaCan Ag Announces Start of Clinical Trial with Glow LifeTech and MGC Pharmaceuticals to Confirm Treatment Potential of Artemic Support in Long Covid Patients

MGC Pharmaceuticals Limited announced that it has received £5.5 million in funding

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10.3 million in funding

Auditors Have Doubts About MGC Pharmaceuticals (ASX:MXC)

Full year 2021 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2020)

MGC Pharmaceuticals Limited Announces Uk Import Permit Granted for Cannepil

Full year 2021 earnings released: AU$0.007 loss per share (vs AU$0.014 loss in FY 2020)

MGC Pharmaceuticals Limited Announces Successful Submission of Self-Nano Emulsifying Cannabinoids-Ionic Complex Concentrate Drug Delivery System

Mgc Pharmaceuticals Limited Announces Phase Iii Cimetra Clinical Trial Commences

MGC Pharmaceuticals Limited Announces Cannabis Derived Epilepsy Investigational Medicinal Product

Mgc Pharmaceuticals Ltd Provides Progress Report on Major Clinical Trial Programs Planned for 2021